Skip to main content
Explore URMC
menu

Sonal S. Munsiff, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-0526

Office: (585) 275-0526

Fax: (585) 273-1055

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Infectious Diseases

Biography

Dr. Sonal Munsiff is board-certified in Infectious Diseases. She manages many acute and chronic infections mostly in the outpatient clinic setting, with particular interest in bone and joint infections, orthopedic hardware, and cardiac device related infections, infections with drug resistant organism, HIV, and mycobacterial infections. She is working with a multidisciplinary staff to manage Outpatient IV antibiotics patients for the institution.

Professional Background

Dr. Sonal Munsiff is board-certified in Infectious Diseases. She manages many acute and chronic infections mostly in the outpatient clinic setting, with particular interest in bone and joint infections, orthopedic hardware, and device related infections, infections with drug resistant organism, HIV and AIDS, and mycobacterial infections. She is working with a multidisciplinary staff to manage Outpatient IV antibiotic patients for the institution. She will be teaching "Epidemiology of Infectious Disease" Course in the Epidemiology Division of the School of Medicine and Dentistry in Fall 2017.
.
Previously she has worked in the field of TB control for 15 years with the NYC Bureau of Tuberculosis Control, and with CDC. She served as the Director of Epidemiology for the Program for several years, and then was Director and Assistant Commissioner of the program for 7 years. She has conducted research on various aspects of TB, particularly drug-resistant TB, complications and treatment of TB in HIV-infected persons, transmission and molecular epidemiology of TB, outbreak investigations, and program evaluation. She was co-investigator for the CDC TB clinical rails Unit on studying Moxifloxacin for TB treatment. She has authored over 60 medical publications, including the NYC "TB manual".

Research

Dr. Munsiff's current research interests include optimal diagnosis and management of osteomyelitis, usefulness of the Interferon gamma release assays for diagnosis of latent TB infection, and diagnosis and management of non tuberculous mycobacterial diseases.

Previously she has worked in the field of TB control for 15 years and has conducted research on various aspects of TB, particularly drug-resistant TB, complications and treatment of TB in HIV-infected persons, transmission and molecular epidemiology of TB, outbreak investigations, and program evaluation. She was co-investigator for the CDC TB clinical rails Unit on studying Moxifloxacin for TB treatment. She has authored over 60 medical publications, including the NYC "TB manual".

Credentials

Education

1989
MD | New York University School of Medicine

Post-doctoral Training & Residency

07/01/1993 - 06/30/1995
Fellowship in Infectious Disease at Montefiore Medical Center-North Division/Wakefield

06/16/1990 - 07/30/1992
Residency in Internal Medicine at Columbia University Irving Medical Center

06/15/1989 - 06/15/1990
Internship in Internal Medicine at Beth Israel Deaconess Medical Center-Main Campus

VIEW ALL expand_more

Clinical Trials

A5418 A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease

Lead Researcher: Sonal Munsiff

This study will determine if the drug, tecovirimat, helps treat people you are infected with monkeypox virus. You must be 18 years of age or older to participate. You must have a positive laboratory test for monkeypox virus within 14 days of enrolling in the study and at least one skin lesion. Participants with severe disease, significant skin conditions, participants with severe immune suppression will receive open-label tecovirimat. Participants who are pregnant or breastfeeding will receive open-label tecovirimat after discussion of the potential risks and benefits. Participants less than 18 years of age will receive open-label tecovirimat. Participants receiving a potent inducing concomitant medication will receive open-label tecovirimat. Once enrolled, study drug administration will be for 14 days. Participants will self-monitor skin and/or mucosal lesions daily through 29 days or resolution (whichever comes first), complete a daily diary of symptoms and complete a daily numerical rating scale for pain assessment. Participants will be seen weekly through day 29 for assessment of HMPXV disease, safety assessments, HMPXV sampling similar to that described for entry, and swabbing of new HMPXV lesions. Participants will be seen at day 57 to assess for possible recrudescence of infection (i.e., new lesions occurring after initial resolution of disease.

View Study Details

Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes

Lead Researcher: Sonal Munsiff

This study will determine if the drug, letermovir, is an anti-inflammatory in adults with HIV and asymptomatic cytomegalovirus (CMV) who are on anti-HIV medications and whose HIV is suppressed. Participants will be randomly assigned to receive either letermovir once daily or no anti-CMV treatment, for 48 weeks. There will be treatment provided in this study. Letermovir is a pill given by mouth once a day that is FDA-approved to prevent CMV disease. There are two study treatment groups. You will have a 50/50 chance of going into one of the two groups. Participants in one group will get letermovir and participants in the other group will not get any additional medications. To Enter the Study, the following must be true about you: • HIV positive, ≥40 years of age • On continuous anti-HIV medications for at least 48 months with no interruptions >7 days • At least 48 months of undetectable viral loads, although a one-time, low-level viral load is OK • Have not made significant change in HIV medication in the past 12 weeks, or plan to make changes during study participation • While people with any CD4 count are eligible, the study is particularly interested in recruiting people with low CD4 counts (i.e., <350 cells/mm3)

View Study Details

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B,B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B.

Lead Researcher: Sonal Munsiff

The purpose of this study is to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are naïve to HBV vaccination. To be eligible you must have the following: - HIV-1 infection - On current HIV-1 antiretroviral therapy (ART) - CD4+ T-cell count ≥100 cells/mm^3 - HIV-1 RNA <1000 copies/mL

View Study Details

Publications

Journal Articles

3/16/2022
Munsiff S, Louie T. "Prosthetic Joint Infections and Rifampin." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2022 Mar 16; Epub 2022 Mar 16.

1/25/2022
Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera M DM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet MH, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S. "Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study." The Lancet. Infectious diseases.. 2022 Jan 25; Epub 2022 Jan 25.

2022
Croix MC, Munsiff SS. "cavitary lung disease progression over a three year period - A case report." IDCases.. 2022 27:e01379. Epub 2022 Jan 05.

VIEW ALL PUBLICATIONS